Behavioral Finance Series · Afternoon Edition · 20 April 2026 Ask any Indian retail investor in April 2026 to name three “interesting” stocks. The names that come up are almost always the stocks that dominated the last two or three
Why serious investors should read segment notes to discover where the real business quality sits, and how Titan’s geographic split strengthens trust in the disclosure.
In 1986, Warren Buffett sat down to write his annual letter to Berkshire Hathaway shareholders and buried, deep inside, a single paragraph that would change how serious investors around the world read an income statement. He introduced a concept he
Published 19 April 2026 (Sunday) MULTIBAGGER SHARES Table of Contents Toggle Segment-Wise Revenue Breakdown: Why Titan Biotech’s One-Segment Biological Products Model Makes the Business Easier to Trust – What It Means for Investors Why Segment Simplicity Matters More Than Investors
How Barber & Odean’s Nobel-adjacent research, validated by SEBI’s own 2024 study of 93% losing retail F&O traders, explains the most expensive cognitive bias on Dalal Street — and the exact checklist long-term investors must adopt before ever placing another
Published 19 April 2026 (Sunday) MULTIBAGGER SHARES Table of Contents Toggle Board Composition and Corporate Governance: Titan Biotech’s independent chair, four independent directors, and 14 board meetings reveal serious oversight – What It Means for Investors Why Board Composition Matters
Deferred tax can quietly change how reported profit should be read. The line is less about jargon and more about timing, profit quality, and whether management disclosure deserves trust.
A rights issue can preserve minority ownership or quietly dilute it. The difference lies in why the company needs money, how management behaves, and whether investors understand their rights entitlement before it lapses.
📅 Published 18 April 2026 (Saturday) Live market snapshot at time of writing (previous trading session, Friday 17 April 2026 close): SENSEX 78,493.54 (+504.86 pts, +0.65%), NIFTY 50 24,353.55 (+156.80 pts, +0.65%), FII net inflow ≈ ₹3,200 Cr. Titan Biotech
📅 Published 18 April 2026 (Saturday) Most Indian investors read the headline profit, glance at the EPS, and close the annual report. They never scroll to Note 38 — or whichever note the company uses for “Segment Information” under Ind
Every investor obsesses over the Profit & Loss statement. A few smart ones dig into the Balance Sheet. But almost nobody — and I mean nobody outside of forensic accountants and seasoned value investors — reads the one disclosure that
📅 Published 18 April 2026 (Saturday) Table of Contents Toggle Why Cement Is India’s Most Underrated Multibagger Hunting Ground in 2026 The 8-Factor Cement Sector Analysis Framework Factor 1 — Installed Capacity & Utilisation Ratio Factor 2 — Geographic Footprint
📅 Published 17 April 2026 (Friday) The single most dangerous mistake in Indian value investing is valuing a company on a single year’s earnings. That year could be a cyclical peak. It could be a pandemic-era one-off. It could be
📅 Published 17 April 2026 (Friday) Every value investor eventually runs into the same painful question: how do you value a quality Indian business when its earnings have temporarily collapsed? Think of a pharma company hit by a one-time USFDA
In the quiet business of reading annual reports — page by page, footnote by footnote — there is one number that separates honest promoters from silent wealth extractors. It doesn’t appear in any popular screening ratio. Retail investors almost never